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A B S T R A C T
The human Constitutive Androstane Receptor (hCAR) is together with the human Pregnane X Receptor (hPXR) a
key regulator of the metabolism and excretion of xenobiotics and endogenous compounds. Inhibition or acti-
vation of hCAR by xenobiotics can alter protein expression, leading to decreased or enhanced turnover of both
xenobiotics and endogenous substances. Impacts from these alternations can potentially disturb physiological
homeostasis and cause adverse effects. Tens-of-thousands of manufactured substances of which humans are
potentially exposed are not tested for their potential to inhibit or activate hCAR. In this study, the U.S.
Toxicology in the 21st Century (Tox21) high-throughput in vitro assay results for hCAR inhibition and activation
were used in a comprehensive in-house process to derive training sets for different potency cut-offs, and to
develop suites of quantitative structure–activity relationship (QSAR) models with binary outputs. Final, ex-
panded models, which include substances from the external validation sets, were developed for select minimum
potency levels. Rigorous cross- and external validations demonstrated good predictive accuracies for the models.
The final models were applied to screen 80,086 EU and 54,971 U.S. substances, and the models predicted around
60% of the substances within their respective applicability domains (AD). Finally, statistical comparisons of
hCAR predictions and QSAR predictions for a number of other endpoints related to e.g. Pregnane X, aryl hy-
drocarbon, estrogen and androgen receptors, as well as genotoxicity, cancer, sensitization and teratogenicity
from the Danish (Q)SAR database were made to explore possible implications related to hCAR antagonists and
agonists. The final models from this study will be made available in the free Danish (Q)SAR Models website.
Predictions made with models from this study for 650,000 substances will be made available in the free Danish
(Q)SAR Database. Predictions from the models developed in this study can for example contribute to priority
setting, read-across cases and weight-of-evidence assessments of chemicals.
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The constitutive androstane receptor (CAR) belongs to the human
nuclear receptor (NR) superfamily, a 48-member group [1,2] of “or-
phan” and “adopted-orphan” NRs [3–5]. In humans, the CAR protein is
encoded by the NR1I3 gene from the NR subfamily 1, group I, member
3. The NR subfamily 1 group I also includes the Vitamin D Receptor
(VDR) and the Pregnane X Receptor (PXR) [6–8]. CAR displays so-
called constitutive activity, meaning that it is active also in the absence
of a ligand [9,10]. Many known CAR agonists are species-specific
[11,12]. CAR is expressed mainly in the liver and small intestine
[1,3,13] and mediates the induction of metabolizing enzymes, such as
cytochrome P450 3A (CYP3A) isoenzymes, conjugation enzymes such
as UDP glucuronosyltransferase family 1 member A1, and transporters
such as P-glycoprotein [14–17]. Along with the NR PXR, CAR is a
principal regulator of the metabolism of xenobiotic compounds
[16,18,19]. PXR and CAR cross-regulate their target genes cytochrome
P450 (CYP) CYP2B and CYP3A [20]. CAR also plays an important role
in the metabolism of a number of endogenous substances such as
thyroid and steroid hormones, cholesterol, bile acids, bilirubin, glucose,
and lipids [16,19].
CAR activation and inhibition are mechanistic endpoints related to a
number of health outcomes. In some cases, the CAR upregulation of
xenobiotic metabolism may lead to increased turnover of hormone and
other endogenous substances leading to decreased levels in the body
[21]. Such interference in the regulation of endogenous hormones may
have negative consequences [22], which can be seen in the Adverse
Outcome Pathway (AOP): 8 (under development) [23]. According to
this AOP, activation of CAR or other NRs like PXR and the aryl hy-
drocarbon receptor (AhR) as a molecular initiating event (MIE) can
cause upregulated thyroid hormone (TH) catabolism, and lead to re-
duced TH levels, which may result in adverse neurodevelopmental
outcomes in mammals [23].
CAR activation can have positive outcomes, and has been found to
ameliorate diabetes [24]. However, CAR activation is also the mole-
cular initiating event, according to AOP: 107 [25] (under review), that
can lead to hepatocellular adenomas and carcinomas in the mouse and
the rat. When mice were exposed to certain xenobiotics, CAR activation
was found to be an important factor for tumor development [9,26,27].
In addition, CAR inhibition may decrease the metabolizing potential in
the body, which leads to decreased turnover of endogenous hormones
as well as decreased detoxification and excretion of xenobiotics [28].
Furthermore, CAR inhibition may lead to hepatic steatosis according to
AOP: 58 (under development) [29].
In an effort to reduce animal testing and increase the toxicity-re-
lated information level on chemical substances, the Organisation for
Economic Co-operation and Development (OECD) and European Union
(EU) have paved the way for increasing regulatory use of quantitative
structure–activity relationship (QSAR) models e.g. through the EU
Registration, Evaluation, Authorization and Restriction of Chemicals
(REACH) regulation [30–32]. QSARs are mathematical models that
predict properties, such as biological activities, based on chemical
structure [33–35]. As QSAR predictions can be rapidly generated for
large inventories of substances, their use is very suited for screening and
priority setting purposes as exemplified by an earlier large-scale QSAR
screening for thyroperoxidase inhibitors by some of the authors of this
article [36]. In some cases, QSAR predictions may be used for a 1:1
replacement of experimental tests [37] but especially for higher tier
health endpoints, QSAR predictions may rather contribute to Integrated
Approaches to Testing and Assessment (IATA) weight-of-evidence
(WoE) assessments or to improve read-across cases.
The primary objective of this study was to develop global binary
QSAR models that can be used for screening purposes and single-
compound identification of possible hCAR antagonists or agonists. A
secondary interest in this study was to process the experimental
training set data specifically for the development of QSAR models for
prediction of minimum potency. We used high-throughput in vitro data
sets from the U.S. Tox21 Program’s quantitative high-throughput
(qHTS) assay for hCAR agonism and for hCAR antagonism [38], and the
results were used to train and validate a number of QSAR models for
hCAR inhibition and activation. The U.S. Tox21 Program applies qHTS
screening with the aim of identifying substances that may adversely
affect human health for priority setting purposes. To date, the Tox21
chemical library holds approximately 10,000 diverse chemical sub-
stances, such as commercial chemicals, pesticides, food additives/con-
taminants, and medical compounds [39].
Human CAR agonism data has previously been used as the basis for
QSAR modeling [40–44]. In one case, the published models were de-
veloped on the qHTS agonism Tox21 data as used in the present study,
though using the Tox21 summary calls as is [40,41]. In the other cases,
modeling of hCAR agonism was done as a continuous endpoint or as
binding preferences between CAR and PXR and using other smaller data
sources [42–44]. We have found no published QSARs developed using
antagonism datasets.
In this study, we developed a set of criteria, which we applied to
process the data for our QSAR model development, including setting a
minimum absolute effect which should be seen at a maximum con-
centration threshold and which should occur at a non-cytotoxic con-
centration. We also filtered out luciferase inhibitors which were pos-
sible false positive agonists or false negative antagonists. The processed
data was used to develop initial models for all concentration thresholds.
All initial models underwent a Technical University of Denmark,
National Food Institute (DTU Food) in-house two times five-fold cross-
validation (CV) and external validations with unused actives and in-
actives. Subsequently, four final expanded models were developed by
including external validation data into the training sets of the corre-
sponding initial models. The final models underwent the same CV
procedure and external validation for specificity (not for sensitivity as
all actives were used in the models). The final models were used to
screen 80,086 structurally diverse substances pre-registered and/or
registered under the EU REACH chemicals regulation, and the 54,971
unique chemical structures from the U.S. Environmental Protection
Agency (U.S. EPA) Collaborative Modeling Project for Androgen
Receptor Activity (CoMPARA) inventory [45]. Use of the predictions
may include: 1) priority setting; 2) single substance WoE IATA assess-
ments; 3) support for read-across cases e.g. to find suitable source
analogs or as part of the basis for making the read-across justification.
In addition, hCAR predictions were statistically correlated with pre-
dictions from 39 other QSAR models from the free, online Danish (Q)
SAR database [64] including PXR binding/activation [36], AhR acti-
vation [46], thyroperoxidase (TPO) inhibition [47], estrogen receptor
(ER) activation, androgen receptor (AR) antagonism [48], as well as
endpoints within genotoxicity, cancer, sensitization and teratogenicity
to explore possible roles for the hCAR receptor in relation to other
biological activities.
The QSAR predictions from these screenings will be published in the
free online Danish (Q)SAR Database. In addition, all final models will
be published in the new free, online Danish (Q)SAR Models (accessible
from the Danish (Q)SAR Database) for real-time prediction of user-
submitted structures and downloads of the detailed results in the (Q)
SAR Prediction Reporting Format (QPRF).
2. Materials and methods
2.1. Experimental datasets, definition of endpoints and developed QSAR-
targeted data processing
To develop our datasets, we used results from the U.S. Tox21
Program available from the Tox21 Data Browser [28] and structures for
the Tox21 substances from PubChem [49]. As part of the U.S. Tox21
Program, the U.S. National Institutes of Health (NIH) screened a total of
9,667 chemical substances for hCAR agonism and antagonism [50,51]
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for which substances in the chemical library were not specifically se-
lected to target hCAR agonism and/or hCAR antagonism. Descriptions
of the chemical structures, hCAR assays and Tox21 data analysis can be
found in more detail in previous publications [52,53].
Under Tox21 qHTS testing, both assays were applied to screen the
approximately 10,000 Tox21 substances for hCAR agonists and an-
tagonists, as well as for cell viability. For the cell culture, Tox21 qHTS
testing used human hepatoma (HepG2) cells transfected with a double-
stable human CAR and CYP2B6-2.2 kb in both agonist and antagonist
mode [54,55]. In addition, both assays screened 16 different con-
centrations with varying concentration ranges among the different
substances [28]. Screening statistics of the agonist assay generated a Z’
factor of 0.687 [53,56], and a coefficient of variance close to
6.04% ± 1.56 [53]. Z’ factors reflect the assay signal dynamic range
and data variation associated with signal measurements. Thus, an in-
dicator of good performance is a Z’ factor above 0.5 [56]. These data-
sets were used as a basis for our study in addition to computer-readable
structure-data files (SDF) on the tested chemicals substances structures
from PubChem: a) AID 1224893 on small molecule antagonists of the
hCAR signaling pathway, and b) AID 1224892 on small molecule ago-
nists of the hCAR signaling pathway. Assay results were provided by the
U.S. Tox21 Program [51,57].
The U.S. Tox21 activity profiling is primarily aimed at identifying
potential mechanisms of action to prioritize substances for further in-
depth toxicological evaluation. As part of the U.S. Tox21 data proces-
sing, concentration–response series (CRS), typically three per substance
per assay, are fit to four-parameter Hill equations. Outcomes are then
ranked into so-called curve classes specific to the Tox21 program, ac-
counting for efficacy, p-value, asymptotes and inflection [52]. Con-
centrations of half-maximal (AC50) rather than absolute activity are
additionally calculated for activity and cell viability. For instance, if the
maximum activity of a substance is 30% inhibition, Tox21′s dose–r-
esponse modeling Hill curve will give an AC50, (i.e. the concentration
that causes half-maximal activity) of 15% inhibition. In the end, half-
maximal AC50 values for activity and cell viability were applied to
make activity outcome summary calls specific to the Tox21 program,
which in some cases also integrated results from additional counter
screens.
Rather than using the Tox21 summary calls [50,51], in this study we
undertook further QSAR-targeted processing of the Tox21 hCAR data
by setting criteria for absolute activity for actives, and just as im-
portantly for QSAR models development purposes, by setting criteria to
only select the most robust inactives (Fig. 1) . This QSAR-targeted
processing was possible because the detailed Tox21 test results for each
of the tested concentrations were available in public repositories. For
the purpose of defining our endpoints, we did not find any information
from regulations, AOPs, scientific literature or other sources that would
tell us which potency cut-offs we should apply to identify the most
relevant agonists/antagonists from a health impact perspective, or, if
certain potency cut-offs formed a better basis for QSAR modeling than
others. We therefore decided to apply different potency cut-offs with a
25% absolute effect occurring at or below six different thresholds:
10 µM, 20 µM, 30 µM, 40 µM 50 µM, and No Upper Limit (NUL),
constructing a data set for each threshold. A lower cut-off equals a
higher minimum potency, which could potentially form the basis for
stronger alerts in a model, given that the training set contains a suffi-
cient number of observations. On the other hand, NUL implies that we
did not impose a concentration cut-off.
For each substance, our QSAR-targeted data processing led to the
assignment of one of the following outcomes: “active”, “inactive”, or
“inconclusive”. Only actives and inactives were used for QSAR devel-
opment and validation. For the data processing, we filtered each test
CRS through in-house tools, specifically developed for determining
active responses with non-cytotoxic concentrations showing at least
25% effect (in absolute value). To accept only the best Tox21 Hill curve
classes for inactives, we required Tox21 Hill curve class 4 (i.e. inactive)
and that the substance exhibited no cytotoxicity up to a 10 µM con-
centration [48]. The complete data processing of each substance for
both hCAR agonism and antagonism for each of the selected con-
centration thresholds (10 µM, 20 µM, 30 µM, 40 µM, 50 µM, and NUL)
fell into five main data steps:
1. For agonism activity, only Tox21 curve classes 1.1, 1.2, 2.1, and 2.2,
(i.e. according to the Tox21 definition of these curve classes, all
complete and incomplete curves with inflection, p-value < 0.05
and efficacy > 3 standard deviations (SD) of control) were ac-
cepted.
2. For antagonism activity, only curve classes −1.1, −1.2, −2.1 and
−2.2, (i.e. according to the Tox21 definition of these curve classes,
all complete and incomplete curves with inflection, p-value < 0.05
and efficacy > 3SD of control) were accepted.
3. The highest concentration with non-cytotoxicity was calculated as
the median for all cell viability CRSs for the analyzed substance,
using the highest concentration with at least 80% viable cells for
each CRS.
4. For agonist “actives”, two-thirds of all hCAR activity CRS for the
substance were required to fulfill the requirement of step 1 and to
have at least 25% effect at a non-cytotoxic concentration (as defined
in “3”) at or below the selected concentration threshold. For an-
tagonist “actives”, two-thirds of all hCAR activity CRS for the sub-
stance were required to fulfill the requirement of step 2 and to have
at least 25% effect at a non-cytotoxic concentration (as defined in
“3”) at or below the selected concentration threshold.
5. Substances for which all hCAR activity CRS were curve class 4 with
no cytotoxicity up to at least 10 µM were assigned “inactive”.
A small number of substances for both agonism and antagonism had
at least 50%, but not two-thirds of, all hCAR activity CRS fulfilling the
requirement of step 4. We considered these substances to be “active”
using expert judgment.
Both hCAR agonism and antagonism assays were luciferase-based.
Under certain circumstances, luciferase inhibitors may stabilize the
enzyme, giving significant increases in luciferase levels in cells relative
to untreated wells within the typical assay incubation time, and po-
tentially leading to increases in luminescent signal in cell-based assays
[58]. We therefore removed luciferase inhibitors which were hCAR
agonist actives or antagonist inactives. As a cell-based luciferase
counter screen specifically for the hCAR agonism and antagonism as-
says was not available, we applied an in chemico luciferase inhibition
screen for all Tox21 substances using the Tox21 conclusions as-is [59].
2.2. Structure curation
All data set structures underwent structure curation after the QSAR-
targeted data processing (Fig. 2). The curation was performed in OASIS
Database Manager (DBM) 1.7.3 [60], including additional algorithms
developed in-house. We identified compounds with acceptable struc-
tures. Only structures exclusively containing atoms from the following
list were kept: H, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, and I.
Records with structure errors identified by OASIS DBM were removed
from the dataset. We then conducted a dissociation simulation by
breaking ionic bonds and “neutralizing” the remaining structures. After
this step, we removed substances containing two or more organic
components, (i.e. “mixtures”), and structures with less than two carbon
atoms from the dataset. Furthermore, to assure that every chemical
structure was only represented once in the data set, identical structures,
(i.e. duplicates), were identified and removed according to the proce-
dure described in Fig. 2.
2.3. Training and external validation sets preparation
For both antagonism and agonism, we split each of the six
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concentration threshold data sets into a training and a validation set
(Fig. 1). For each data set, we randomly selected 20% of the active
structures and assigned them to the validation set. The remaining 80%
active structures were then assigned to the training set. Afterwards, we
randomly selected ten times as many training set inactives to create a
training set with a 1:10 distribution. This distribution represented the
maximum ratio that the applied QSAR modeling software could effi-
ciently model. Any remaining inactives were used for the validation set.
This meant that for external validation sets, inactives greatly out-
numbered the actives. Only after the models were fully developed, we
applied the external validation sets in an independent external
validation (i.e. external validation was not used to select models).
Last, we combined the training set and the external validation set
for each of a number of selected concentration thresholds to create four
final, expanded models, namely for the 20 µM and 50 µM concentration
thresholds for both hCAR antagonism and hCAR agonism (Fig. 1). An
aim of the expanded models was to possibly improve model accuracy,
robustness and/or applicability domain of the models. Due to the 1:10
limitation, some negatives were randomly left out of the expanded
models. These negatives were later applied to make independent ex-
ternal validations for specificity for the expanded models.
Figure 1. Overview of the process of making training and validation sets, modeling, and predictions for hCAR antagonism and agonism activity. The rectangular
boxes are for experimental data sets, the ovals are for models and the triangles are for the screening sets. The process was performed for both the agonism and
antagonism sets.
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2.4. QSAR modeling and selection
To develop all models for both antagonism and agonism, we used
the commercial software Leadscope® Predictive Data Miner (LPDM), a
component of Leadscope® Enterprise Server version 3.5.3-5 [61].
Structures were first imported into LPDM. Upon import, nine con-
tinuous molecular descriptors (AlogP, hydrogen bond acceptors and
donors, Lipinski score, molecular weight, parent atom number, parent
molecular weight, polar surface area, rotatable bonds) were calculated
for each structure. Imported structures also underwent LPDM’s sys-
tematic substructure analysis for indexing according to 27,000 pre-de-
fined 2D fragment descriptors called “features” [62,63]. LPDM allows
the user to generate additional training set-dependent 2D fragment
descriptors called “scaffolds,” which may or may not coincide with the
original feature library. From the entire descriptor set, which includes
structural features, scaffolds and molecular descriptors, LPDM auto-
matically selected the top 30% descriptors using the Yates X2-test.
LPDM models binary response variables using partial logistic regression
(PLR). A description of the PLR method in LPDM is available in a
publication by Valerio et al. [64], which also refers to other publica-
tions on the topic and examples of the performance of LPDM PLR
models. Briefly, as described in [59],
“PLR is used for a binary response variable and extracts factors by
PLS using the responses as continuous data followed by logistic re-
gression for classifications; this process is repeated until the criteria
for optimum number of factors and features are reached. The binary
classification model results are given as outcome probabilities from
the logistic regression.”
Training sets skewed towards a greater number of negatives,
however, can lead to models with a higher specificity, (i.e. bigger
proportion of the negatives being correctly predicted), at the expense of
the sensitivity, (i.e. smaller proportion of the positives being correctly
predicted) [64]. LPDM, therefore, offers the option of developing
composite models, a method bearing some resemblance to bagging [65]
though with full resampling of the smaller class and without replace-
ment of the larger class. With this option, the modeler can set the de-
sired ratio between the two activity classes and include up to ten sub-
models with a 1:1 ratio, resampling the smaller class. The sub-models
are aggregated to form a composite model. When such a model is used
for prediction, the test structure is first predicted by all sub-models
individually, and the composite model positive prediction probability is
defined as the average positive prediction probability over all sub-
models where the test structure is in the defined applicability domain
[64]. In our experience, composite models have close-to-equal sensi-
tivity and specificity. In previous research by some of the authors, a
“cocktail” model approach was made where the sub-models of com-
posite models are further aggregated with a model on the full skewed
training set (“single model”) [47]. In earlier work this has been shown
to most often increase specificity with only a small penalty on sensi-
tivity compared to the composite models, thus increasing the balanced
accuracy compared to either the composite or single models [46].
With the purpose of selecting the specific modeling approach for
further hCAR model development, we used the following approaches
for all six agonism and six antagonism concentration threshold training
sets in the initial model development:
1. single model, i.e. a non-composite model drawing on the full
training set
2. composite model, i.e. 10 sub-models
3. composite cocktail model, i.e. single model combined with the 10
composite sub-models
For all models, scaffolds were generated in LPDM from the training
set structures and used with the continuous descriptors and features. All
models underwent a two-times five-fold CV (i.e. removing 20% and
making models on the remaining 80% structures to predict the 20%
leave-out) by the LPDM algorithm. Currently, LPDM’s variable selection
algorithm transfers knowledge of the selected descriptor set from the
parent model when developing the CV sub-models. As a result, LPDM’s
CV may give overly optimistic results. Thus, LPDM’s CV was only used
to assess the relative performance of the initial models for modeling
approach selection. In the end, we selected a number of concentration-
thresholds for antagonism and agonism, for which we used the ex-
panded training set made from initial training set and validation set for
that concentration threshold to develop new, expanded models (Fig. 1).
2.5. Applicability domain definition
We defined the applicability domain (AD) of our models as a com-
bination of the following three components: 1) model-independent
structure requirements; 2) LPDM’s definition of a structural domain; 3)
DTU Food’s in-house definition of class probability refinement on the
LPDM’s output. We considered a test structure to be in AD if:
1. The test structure exclusively contained H, B, C, N, O, F, Na, Mg, Si,
P, S, Cl, K, Ca, Br, and/or I, it was mono-constituent after de-salting,
and it contained at least two carbon atoms.
2. The test structure met the following LPDM criteria:
a) LPDM’s algorithms can calculate all molecular descriptors for the
structure
b) the structure of the compound contains at least one structural
feature used in the model
c) the structure of the compound has at least 30% similarity using
the Jaccard [66] (also known as Tanimoto) coefficient [64,p.
509,513] with a training set substance (based on Leadscope’s
Figure 2. Data processing and structure curation.
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built-in fragment library).
3. The test structure met the following criteria based on the positive
prediction probability p between 0 and 1 calculated by LPDM as part
of the prediction, with actives having a p ≥ 0.5 and inactives having
a p < 0.5 [64,513]: p ≥ 0.7 is required for an active prediction call
and a p ≤ 0.3 for an inactive prediction call. Predictions closer to
the cutoff (p = 0.5) are excluded, as they are likely to be less reli-
able.
2.6. Validation of the models
After using LPDM to guide the selection of the modeling approach,
we applied DTU Food’s two-times five-fold CV procedure to measure
the robustness and performance of the initial antagonism and agonism
models (Fig. 1). In this procedure, all DTU Food CV sub-models were
developed in isolation from the parent model as completely new models
in Leadscope. The DTU Food’s CV conditions prevent any transfer of
knowledge from the parent model to the CV sub-models. The five-fold
approach was chosen as a robust leave-many-out CV approach, and
because removing a higher proportion of actives might cause too large
of a perturbation in the training set for the relatively small active class.
To execute the DTU Food five-fold CVs, we first randomly divided
the training set into five portions, each constituting 20% of the training
set structures while preserving the ratio of inactives to actives (10:1).
For each of these five portions, the following steps were taken:
1. the 20% portion was removed from the full training set to create a
sub-model’s training set of 80%.
2. a CV sub-model was built from the reduced training set by applying
the same development approach as for the parent model, but
without transferring any variable selection information.
3. the 20% left-out portion was predicted by the 80% sub-model.
The whole procedure was performed twice, resulting in 10 CV
prediction sets per concentration threshold model. For all in-AD pre-
dictions for each concentration threshold model’s 10 prediction sets, we
also calculated overall sensitivity, specificity and balanced accuracy as
well as standard deviations (SD) between prediction results in the ten
sub-models [67]. In our study, we used Cooper et al.’s definitions: a)
sensitivity is defined as the percentage of experimental actives pre-
dicted accurately; b) specificity is the percentage of experimental in-
actives predicted accurately; c) balanced accuracy (BA) as the average
of specificity and sensitivity [67]. We chose these statistical measures of
performance as they are particularly appropriate for our cases of
models with very imbalanced training sets, as they all three are in-
dependent of the balance between the active and inactive class. To
determine the percentage of substances with predictions within the AD
of the DTU Food CV models, we calculated the total coverage or “the
proportion of the full set predicted within the AD of the model” of each
threshold concentration model’s total 10 CV models [47].
To further evaluate the predictive performance of the initial DTU
Food cross-validated threshold-concentration models for antagonism
and agonism, we subjected these models to external validations using
the set aside validation sets (Fig. 1). Predictions, which were within AD,
were then compared with the experimental results. Sensitivity, speci-
ficity, balanced accuracy and coverage were calculated for each model.
Likewise, we applied the DTU Food CV procedure to the expanded
antagonism and agonism models for the selected concentration
thresholds (Fig. 1). Since all expanded models contained all of the ac-
tives from the QSAR-targeted Tox21 data processing, an external vali-
dation could only be performed for specificity with the inactives that
were not included in the expanded models. Compliance with the OECD
(Q)SAR validation principles for all four expanded models was docu-
mented in (Q)SAR Model Reporting Format (QMRF) reports.
2.7. Screening large chemical inventories
To identify possible hCAR activators and inhibitors among current
industrial chemicals, we applied the expanded QSAR models to predict
two, large regulatory chemical libraries: the REACH pre-registered and/
or registered substances compiled for the Danish (Q)SAR Database
[68,69], and a U.S. EPA substance list compiled for the U.S. EPA
CoMPARA project [70] (Fig. 1). Both the REACH substances and U.S.
EPA set already underwent a similar structure preparation as described
in 2.2. For our study, 80,086 QSAR-ready REACH structures, and
54,971 QSAR-ready U.S. EPA inventory structures were screened by the
expanded QSAR models. As part of the prediction analysis, we calcu-
lated the proportion of QSAR-predicted U.S. EPA and REACH-PRS
substances within the AD, and of these, how many were predicted as
active or inactive.
2.8. Statistical correlations of hCAR predictions with QSAR predictions for
other endpoints
To investigate possible statistical (not necessarily causal) associa-
tions between hCAR and hPXR, hAhR, hER, hAR, mutagenicity, sensi-
tization, cancer and teratogenicity, we correlated screening results from
the REACH set with Leadscope® QSAR predictions on other endpoints
contained in the DTU Food-developed Danish (Q)SAR Database.
Detailed information for free download on the applied Leadscope®
QSAR models can be found in the QSAR Model Reporting Format
(QMRF) from the Danish (Q)SAR Database [69]. To gauge the strength
of the correlations, specifically for predictions found in the common
domain between each of the individual hCAR models and each of the
individual other models, we calculated Matthews correlation coefficient
(MCC), chi-square (χ2) test statistic, and statistics for how good the
hCAR models are at ‘catching’ actives from other models as well as how
often hCAR models give positive predictions when the other models
predict negative, and how good other models are at ‘catching’ actives
from the hCAR models as well as how often the other models give
positive predictions when the hCAR models predict negative.
3. Results and discussion
In this study we developed and validated QSAR models for hCAR
antagonism and hCAR agonism for a number of different effect con-
centration thresholds and used final expanded models for 25% absolute
effect at maximum 20 µM and 50 µM to screen 80,086 REACH sub-
stances and 54,971 U.S. EPA substances for hCAR antagonism and
agonism.
3.1. The training and validation sets
We started with Tox21 experimental results for 9,667 substances for
both hCAR antagonism and hCAR agonism from the Tox21 Data
Browser and structures from PubChem. After subjecting the initial data
to our QSAR-targeted data processing and structure curation, data sets
were reduced to less than half of the original dataset size. Detailed
results from the QSAR-targeted data processing, structure curation, and
splits into training and validation sets for the individual concentration
thresholds can be viewed in Table 1.
3.2. QSAR modeling and selection
QSAR models were developed in LPDM based on all initial training
sets using the three different modeling approaches. Furthermore, they
were cross-validated by the LPDM two times five-fold CV (Table 2). In
all but one case (agonism 10 µM), the cocktail (“3”) models had the
highest balanced accuracies, due to increased specificities and only
slightly decreased sensitivities compared to the composite (“2”) models.
We, therefore, chose to continue with the cocktail models.
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Our next step was to choose concentration thresholds for which we
would expand the training sets with substances from the validation sets.
For both the antagonism and the agonism initial models, the differences
in the LPDM results for the cocktail models across all concentration
thresholds were small and did not point to any concentration threshold
standing out as giving better results (Table 2). For both antagonism and
agonism, we chose the 20 μM and 50 μM models for further work with
expansion and screening. The 20 μM models were chosen to predict
higher potency substances and the 50 μM models were chosen to be
able to make a wider screening of possible hCAR substances while still
being able to interpret the predictions for minimum potency, which
would not be possible with the NUL models. More specifically, an active
prediction from a 50 μM model means that the chemical is predicted to
have minimum 25% effect at maximum 50 µM concentration, i.e. a
minimum potency. The 10 μM models were not chosen for higher po-
tency prediction since especially for agonism the model had a quite
small number of actives in the training set and was therefore more
unstable and with smaller AD than the 20 μM model. The 20 μM and
50 μM expanded models for both hCAR antagonism and hCAR agonism
were made using the expanded training sets presented in Table 1 and
using the chosen cocktail approach in LPDM.
3.3. Predictive performance of the initial QSAR models
All initial antagonism and agonism QSAR models underwent a two-
times five-fold DTU Food in-house CV procedure as well as external
validation with the left out 20% actives and all remaining inactives
(Table 3). For antagonism, DTU Food CV sensitivities ranged between
54.3% and 74.7%. With rather high SD values (i.e. 11.5% and 16.1%,
for Ant-20 µM-QSAR and Ant-30 µM-QSAR, respectively), the CV sen-
sitivities were, in fact, not significantly different from each other. The
high standard deviations (SD) of sensitivities for the CV results of both
endpoints are likely due to the 20% removal from the relatively small
sets of actives, which removes valuable information for chemical classes
not highly represented in the sets (Table 3). In contrast, CV specificities
ranged between 92.4% and 97.2%. These high specificities had a
Table 1
Number of processed substances through QSAR-targeted data processing and structure curation, and resulting unique structures in the training and validation sets
with the distribution of active and inactive.
hCAR Antagonism hCAR Agonism
All Active Inactive All Active Inactive
Start set 9667 – – 9667 – –
10 µM
After QSAR-targeted data processing 5868 160 5708 6977 108 6869
Acceptable structures 5430 136 5294 6422 106 6316
After luciferase inhibitors removal 5298 136 5162 6356 40 6316
After duplicates removal 4259 107 4152 5098 33 5065
Validation set (20% random for actives) 3313 21 3292 4812 7 4805
Training set (inactives = 10 * actives) 946 86 860 286 26 260
20 µM
After QSAR-targeted data processing 5897 189 5708 7098 229 6869
Acceptable structures 5459 165 5294 6609 227 6382
After luciferase inhibitors removal 5327 165 5162 6492 110 6382
After duplicate removal 4277 128 4149 5147 84 5063
Validation set (20% random for actives) 3155 26 3129 4410 17 4393
Training Set (inactives = 10 * actives) 1122 102 1020 737 67 670
Expanded training set 1408 128 1280 924 84 840
Reduced validation set (only inactives) 2869 4223
30 µM
After QSAR-targeted data processing 5920 212 5708 7126 257 6869
Acceptable structures 5481 187 5294 6636 254 6382
After luciferase inhibitors removal 5349 187 5162 6507 125 6382
After duplicate removal 4292 144 4148 5159 96 5063
Validation set (20% random for actives) 3027 29 2998 4312 19 4293
Training Set (inactives = 10 * actives) 1265 115 1150 847 77 770
40 µM
After QSAR-targeted data processing 5925 217 5708 7129 260 6869
Acceptable structures 5485 191 5294 6639 257 6382
After luciferase inhibitors removal 5353 191 5162 6509 127 6382
After duplicate removal 4292 145 4147 5161 98 5063
Validation set (20% random for actives) 3016 29 2987 4303 20 4283
Training Set (inactives = 10 * actives) 1276 116 1160 858 78 780
50 µM
After QSAR-targeted data processing 5956 248 5708 7267 398 6869
Acceptable structures 5515 221 5294 6774 392 6382
After luciferase inhibitors removal 5383 221 5162 6592 210 6382
After duplicate removal 4314 170 4144 5234 173 5061
Validation set (20% random for actives) 2818 34 2784 3716 35 3681
Training Set (inactives = 10 * actives) 1496 136 1360 1518 138 1380
Expanded training set 1870 170 1700 1903 173 1730
Reduced validation set (only inactives) 2444 3331
NUL∔
After QSAR-targeted data processing 5961 253 5708 7341 472 6869
Acceptable structures 5519 225 5294 6848 466 6382
After luciferase inhibitors removal 5387 225 5162 6641 259 6382
After duplicate removal 4315 172 4143 5271 212 5059
Validation set (20% random for actives) 2797 34 2763 3401 42 3359
Training Set (inactives = 10 * actives) 1518 138 1380 1870 170 1700
∔ For No Upper Limit (NUL) a concentration threshold cut-off was not set.
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smaller SD range of values, (i.e. 1.2% to 2.9%), which reflected the
larger inactive classes in the training sets. Balanced accuracies stayed
between 75.7% and 84.0% (Table 3). For the agonism models, CV
sensitivity was much lower for the Ag-10 µM-QSAR, (i.e. 28.2%) and
ranged between 61.6% and 71.7% for the remaining models (Table 3).
Relative to the antagonism values, SD values were in some cases higher
(i.e. between 12.2% and 32.3%). Higher SD values reflected the rather
small size of the training set active classes. For example, the Ag-10 µM-
QSAR initial model had only 26 actives compared to the Ant-10 µM-
QSAR initial model with 86 actives. On the other hand, the CV-derived
specificities for the initial agonism models ranged between 90.0% and
93.0%. Similar to the antagonism models, these high specificities were
attributed to larger inactive classes in the training sets. SD values
ranged between 2.2% for the Ag-No-Upper-Limit initial model and
Table 2
Results from the LPDM 2 times five-fold CV of all initial models by three ap-
proaches: 1) single model, 2) composite model, 3) composite cocktail model to
guide selections of modeling approach and concentration threshold.
Initial models Approach LPDMs two times five-fold cross validation results





1 54.1 99.0 76.6
2 91.2 89.9 90.6
3 86.6 97.4 92.0
20 µM training
set
1 49.3 98.6 74.0
2 87.8 88.3 88.1
3 84.5 97.8 91.2
30 µM training
set
1 52.9 98.5 75.7
2 87.2 89.1 88.2
3 84.9 97.2 91.1
40 µM training
set
1 47.3 98.9 73.1
2 87.8 87.3 87.6
3 85.9 97.4 91.7
50 µM training
set
1 46.0 99.0 72.5
2 84.1 87.2 85.7
3 83.5 97.9 90.7
No Upper Limit
training set
1 38.5 99.0 68.8
2 84.6 86.3 85.5




1 23.5 99.4 61.5
2 94.7 88.2 91.5
3 81.3 96.8 89.1
20 µM training
set
1 35.8 98.9 67.4
2 96.6 89.0 92.8
3 92.5 96.9 94.7
30 µM training
set
1 21.1 99.5 60.3
2 91.4 88.8 90.1
3 87.7 98.0 92.9
40 µM training
set
1 41.8 98.2 70.0
2 92.2 88.2 90.2
3 90.2 96.5 93.4
50 µM training
set
1 40.4 98.6 69.5
2 92.0 87.6 89.8
3 90.3 97.9 94.1
No Upper Limit
training set
1 24.5 98.8 61.7
2 91.0 87.2 89.1
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6.3% for the Ag-10 µM-QSAR initial model. Balanced accuracies had a
slightly lower range between 55.0% and 81.4%. From the results in
Table 3 for the initial models for the different concentration thresholds
there was no clear trend in the accuracy and robustness of the models,
except that the two smallest agonism models, i.e. the Ag-10 µM-QSAR
and Ag-20 µM-QSAR, were less robust than the other agonism models,
likely due to the small active class. In fact, the SDs were overlapping
between the different antagonism models and between the different
agonism models. This lack of clear trends in the accuracies of the
models for different concentration thresholds could potentially be due
to: 1) the substances tested positive at higher concentrations could be
just as distinct members of the active structure class as the substances
tested positive at lower concentrations, 2) the uncertainties due to the
modeling procedure could be bigger than the model accuracy difference
between thresholds, 3) the experimental test results could have bigger
uncertainties than the model accuracy differences between thresholds
(despite a good Z’ factor), or 4) a combination of some or all of the
above. For the four expanded models the accuracies are not sig-
nificantly higher than for the corresponding initial models, however
except for the Ant-20 µM-QSAR the SD decreases in the expanded
models, indicating higher robustness of the expanded models compared
to the corresponding initial models.
Unlike the CV sensitivities, external validation with the 20% left-out
actives and the remaining inactives resulted in a wider range of sensi-
tivities for both antagonism and agonism models, though specificities
remained relatively high and within a narrow range. For antagonism,
the sensitivities ranged between 55.0% for the Ant-50 µM-QSAR initial
model and 83.3% for the Ant-20 µM-QSAR initial model (Table 3).
Specificities, however, were higher, i.e. between 91.7% for the Ant-No-
Upper-Limit initial model and 94.2% for the Ant-10 µM-QSAR initial
model. The range for balanced accuracy was also slightly wider (i.e.
73.8% to 88.4%) when compared to the CV balanced accuracies (i.e.
75.7% to 84.0%).
External validations for agonism gave sensitivities between 37.5%
for the Ag-30 µM-QSAR initial model and 100.0% for the Ag-10 µM-
QSAR initial model (Table 3). Specificities ranged between 89.4% for
the Ag-No-Upper-Limit initial model and 95.3% for the Ag-10 µM-QSAR
initial model. Balanced accuracies ranged between 65.0% and 97.6%
for the Ag-30 µM-QSAR and for the Ag-10 µM-QSAR initial models,
respectively.
For both antagonism and agonism, sensitivities lacked a clear trend,
and varied much more than specificities. Variance was most likely due
to the small number of actives in AD in the validation sets, as reflected
in the true positive (TP) and false negative (FN) numbers (Table 3). On
the other hand, specificities were much more stable due to the high
number of inactives in the validation sets. High specificities are desir-
able because it means that the models do not generate a high percen-
tage of false positives, which is important especially for endpoints with
low prevalence, like hCAR antagonism and agonism. A possible trend
for both antagonism and agonism models could be the slight decrease in
specificity with increasing concentration thresholds. This slight trend
could possibly indicate that including actives with lower potency in the
training set leads to decreasing quality of the positive alerts in the
models. Because of the uncertainties of the sensitivities, comparisons
between CV results and external validation results are most relevant for
specificity. As shown in Table 3, the specificities from the external
validations are close to the specificities from the CVs, with the latter
being a few percent higher (SD taken into consideration) in some cases.
Documentation of the four expanded models in QMRF reports is
available from the Danish (Q)SAR Database [69].
3.4. Predictive performance of the 20 µM and 50 µM expanded QSAR
models
All expanded QSAR models underwent a two-times five-fold DTU
Food CV procedure as well as external validation for specificity using
the inactives not included in the expanded training sets (Table 3). Ac-
cording to the DTU Food CV results, the expanded antagonism 20 µM
and 50 µM models had sensitivities of 58.4% and 72.4%, specificities of
97.1% and 91.6%, and BAs of 77.8% and 82.0%. For the expanded
agonism 20 µM and 50 µM models, sensitivities were 72.2% and 78.4%,
specificities were 93.5% and 91.4%, and BAs were 82.8% and 84.9%. In
all cases, the results for the expanded antagonism and agonism models
were not dissimilar from the CV results of the corresponding initial
models, taking SD into account. With the exception of sensitivity for the
20 µM antagonism model, for both antagonism and agonism, the SDs
for sensitivity and specificity were, in all cases, lower for the expanded
models than the corresponding initial models, thus, indicating more
stability.
When looking at the external validation results, the expanded an-
tagonism 20 µM and 50 µM models had specificities of 93.4% and
92.4%. For the expanded agonism 20 µM and 50 µM models, external
validation specificities were 91.5% and 90.6%. Notably, the specificity
results for all antagonism and agonism expanded models had a differ-
ence of < 1% from the external validation specificity results for the
corresponding initial models. Although smaller than the 50 µM models,
the 20 µM antagonism and agonism expanded models had slightly
higher external validation specificities on these relatively large inactive
validation sets. We, therefore, speculated that some less discriminating
positive alerts entered into the 50 µM model compared to the 20 µM
models, especially for antagonism, when weaker actives were included
in the training set.
3.5. Screening results
We screened the U.S. EPA and REACH inventories using the ex-
panded models for hCAR 20 µM and 50 µM antagonism and agonism
(Table 4). The 20 µM and 50 µM antagonism models had coverages
between 54.3% and 63.1% (with the 50 µM model having the lower
coverages in accordance with external validation results from Table 3),
Table 4
The coverage (AD) and the number of active/inactive predictions of the U.S. EPA and REACH inventories in the expanded 20 µM and 50 µM hCAR antagonism models
and the expanded 20 µM and 50 µM hCAR agonism models.
Datasets No. substances Ant-20 µM-QSAR (expanded) Ant-50 µM-QSAR (expanded)
In AD Active (%) Inactive (%) In AD Active (%) Inactive (%)
REACH† 80,086 63.1% 8,058 (16.0) 42,441 (84.0) 57.0% 7,680 (16.8) 37,931 (83.2)
U.S. EPA†† 54,971 59.6% 5,175 (15.8) 27,577 (84.2) 54.3% 5,062 (17.0) 24,767 (83.0)
Datasets No. substances Ag-20 µM-QSAR (expanded) Ag-50 µM-QSAR (expanded)
In AD Active (%) Inactive (%) In AD Active (%) Inactive (%)
REACH† 80,086 61.1% 8,265 (16.9) 40,631 (83.1) 63.7% 10,289 (20.2) 40,711 (79.8)
U.S. EPA†† 54,971 59.8% 5,731 (17.4) 27,121 (82.6) 63.0% 7,254 (20.9) 27,389 (79.1)
† REACH pre-registered and/or registered substances.
†† U.S. EPA inventory of man-made chemical structures to which humans are potentially exposed.
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and predicted between 15.8% and 17.0% substances as being active
within their respective ADs from the two inventories. The 20 µM and
50 µM agonism models, on the other hand, had coverages between
59.8% and 63.7%, and predicted between 16.9% and 20.9% of the
substances in AD from the two inventories to be active. The prevalences
of actives among the tested Tox21 substances were between 2.5% and
4.0%, depending on the concentration threshold, after we did the
QSAR-targeted data processing (prevalences can be derived from
Table 1). While the experimentally tested Tox21 library of substances
was not selected based on suspicion of hCAR antagonism or agonism, it
is not known how well the library reflects the true prevalence of hCAR
antagonists and agonists of the U.S. EPA and REACH inventories. As
shown by the rather large external validations, both the applied an-
tagonism and the agonism models showed high specificities
(90.7%−93.2%), indicating that they do not give many false positive
predictions. Nevertheless, as can be derived from the external valida-
tion specificity results the models may still have false positive rates of
around 6.8%−9.3%. These false positive rates may explain some
though not all of the high percents, (i.e. 15.8%−20.9%), of active
predictions for hCAR antagonism and agonism in the two large in-
ventories, thereby indicating a possible high number of hCAR antago-
nists and agonists in the U.S. EPA and REACH inventories.
3.6. Statistical correlations of hCAR predictions with QSAR predictions for
other endpoints
To explore possible biological pathways and toxicity properties af-
fected by hCAR antagonists and agonists, REACH screening results for
both the expanded hCAR 50 µM antagonism and agonism models were
statistically correlated with QSAR predictions within the same REACH
set using DTU Food-developed and commercial LPDM QSAR models for
endpoints related e.g. to PXR, AhR, ER, AR, TPO, mutagenicity, cancer,
sensitization and teratogenicity endpoints (Table 5).
In Table 5 A and B for correlations with hCAR antagonism and
agonism predictions, respectively, the rows are sorted by column
“hCAR Pos of M1 Pos (%)” in descending order. At the top of both lists,
there are endpoints related to AhR, AR, ER, PXR/CYP3A4, cancer in rats
and TPO. More specifically, hCAR positive predictions are found at a
much higher percentage among positive rather than among negative
predictions from models for these endpoints. To investigate the risk of
chance correlations from the results given in Table 5, we calculated
Pearson χ2 test (one degree of freedom) probabilities for being chance
correlations and almost all of them are nearly 0 (< 1E-10, results not
shown). In addition we calculated false discovery rate by Benjamini-
Yekutieli procedure with alpha equal to 1E-18 (i.e. extremely low risk
of chance correlation). With the exception of a few (which had absolute
MCC values < 0.05 in Table 5 A and B), all correlations rejected the
null hypothesis, i.e. were found not to be chance correlations by this
test.
These statistical correlations of QSAR predictions between CAR and
another endpoint indicate overlap in the chemical classes predicted
positive for both endpoints as well as negative for both endpoints. To
identify classes of substances that induce hCAR agonism, Lynch et al.
grouped the Tox21 primary screen of 10,000 substances based on their
structural similarities into 1,014 clusters, of which 62 clusters were
significantly enriched with hCAR activators [53]. These clusters in-
cluded the known CAR activators flavones and prazoles as well as a
potential novel cluster containing nitazoxanide and tenonitrozole. It is
known that CAR shares response elements with PXR [71] and that the
two receptors have a significant overlap in their ligand specificities
[53]. It is likewise known that CAR and PXR coordinate the metabolism
and excretion of xenobiotic substances together with AhR [72]. As
shown in Table 5, both hCAR antagonism and agonism correlated
strongly with PXR and even more strongly with AhR. We therefore
wanted to explore further how well QSAR predictions from the hCAR
agonism model correlated with QSAR predictions from our earlier
models on PXR and AhR agonism [36,46] in a trilateral analysis.
The tabulated counts in Table 6 show that 23,004 substances out of
80,086 REACH substances in the Danish (Q)SAR Database are in the
common domain of the three models. Of these 23,004 substances, the
vast majority were predicted negative by all three models, (i.e. 20,164
substances or 88%). hCAR had 561 positive predictions, for which the
other two models predicted negative (corresponding to 2% of the
common domain), hPXR had 738 (3%) positive predictions, for which
the two other models predicted negative, and hAhR had 21 (0.1%)
positive predictions, for which the two other models predicted negative.
However, all three models gave positive predictions for 243 substances.
hCAR and hPXR shared the biggest number of common positive pre-
dictions, namely the 243 substances which were positive in all three
models, plus 1,233 substances only positive in the hCAR and hPXR
models, in total 1,476 (6%). In addition, the AhR model rarely gave a
positive prediction when the hCAR model gave a negative prediction,
(i.e. 21 plus 3 cases).
4. Conclusions
Our study presents two main results. First, we developed an in-
house QSAR-targeted data processing approach to extract Tox21 ex-
perimental results for QSAR development of different absolute
minimum potency classes. Second, we developed, validated, and ap-
plied global, binary QSAR models for hCAR antagonism and agonism in
vitro. All initial models were based on 10 µM, 20 µM, 30 µM, 40 µM,
50 µM and No Upper Limits threshold concentrations for both agonism
and antagonism. All initial models underwent DTU Food CV and ex-
ternal validation and showed high specificities of around 90–95% and
good balanced accuracies, (i.e. 75.7–84.0% for CV and 65.0–97.6% for
external validation). For both antagonism and agonism, new, expanded
models were developed for the 20 µM and 50 µM thresholds by in-
corporating the external validation set actives and ten times as many
inactives into the training sets. These expanded models also underwent
DTU Food CV and external validation for specificity, only as there were
no additional actives for a full external validation. In all but one case,
the results for the expanded antagonism and agonism models were
slightly better compared to the corresponding initial models. However,
taking SD into account, the results were not dissimilar from the DTU
Food CV results related to their corresponding initial models. External
validations of specificity showed similar performance between initial
and the corresponding expanded models.
Our four expanded models were used to screen two, large chemical
inventories from the U.S. and EU. Of the substances predicted within
the ADs of the expanded models, the 20 µM agonism model predicted
8,265 (16.9%) REACH substances and 5,731 (17.4%) U.S. EPA sub-
stances to be positive; the 20 µM antagonism model predicted 8,058
(16.0%) REACH substances and 5,175 (15.8%) U.S. EPA substances to
be positive. For antagonism, the 50 µM expanded model predicted a
slightly lower number of positives than the 20 µM expanded model due
to fewer substances in the AD. For agonism, the 50 µM expanded model
predicted a slightly higher number of positives than the 20 µM ex-
panded model. Finally, we explored if a number of biological pathways
and toxicity properties correlated statistically, (i.e. not causally), with
predicted hCAR antagonists and agonists. This was done by correlating
QSAR predictions from the expanded hCAR 50 µM antagonism and
agonism models with QSAR predictions for endpoints related to PXR,
AhR, ER, AR, mutagenicity, sensitization, cancer and teratogenicity
endpoints for 80,086 REACH substances contained in the Danish (Q)
SAR Database. A number of strong statistical correlations were found to
e.g. other receptor endpoints, genotoxicity endpoints and rodent car-
cinogenicity.
Predictions from the developed hCAR antagonism and agonism
QSAR models may be utilized in the future to support e.g. screening and
priority setting, read-across and IATA WoE assessments. Predictions for
650,000 substances from the expanded antagonism and agonism 20 µM
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and 50 µM models along with their QMRFs, as well as training and
validation sets for all initial and expanded models, will be published in
the free online Danish (Q)SAR Database, and the four expanded models
will be made available via the free online Danish (Q)SAR Models
website [69].
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